US physicians will require less clinical trial data than European peers before they are comfortable Rxing biosimilars; report

US physicians will require less clinical trial data than physicians in Europe before they are comfortable prescribing biosimilars. According to Biosimilars Advisory Service: Acceptance of Biosimilars Across Physician Specialties from Decision Resources, 33% of surveyed US physicians would feel comfortable prescribing a biosimilar that launched with only one Phase III study for support, compared with an average of 20% of peers in France and Germany. Compared with French and German physicians, US physicians are comfortable with the shortest duration of clinical trials.

"The desire for trials addressing immunogenicity of biosimilars is greater among European physicians compared with physicians in the United States, and likely reflects immunogenicity problems with biosimilars erythropoiesis stimulating agents currently on the market in the European Union," said Decision Resources product director Michael Malecki.